Evaluation of appropriateness of meropenem treatment and outcomes among internal medicine patients in Thailand
- 1Division of Infectious Diseases, Internal Medicine Department, Lampang Hospital
- 2Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University
Abstract
Objective Carbapenems are commonly used empirically in referral hospitals; however, the appropriateness and outcomes of meropenem use in regional settings with rising multidrug resistance remain unclear. Methods A retrospective cohort study of 528 patients who received at least 1 dose of meropenem in the internal medicine ward at Lampang hospital, Thailand during the study period (1 August 2022 and 31 December 2022). Results A total of 528 patients were enrolled. Of these, 281 (53.22%) were survivors, while 247 (46.78%) were non-survivors. Gram-negative bacteria were the most common infections, with 28.2% susceptible to carbapenems. The most frequent pathogens were Acinetobacter baumannii (16.7%), followed by Escherichia coli (13.6%) and Klebsiella spp. (8.0%). Pneumonia (36.93%) and urinary tract infection (21.97%) were the most common sites of infection. Appropriate empirical meropenem use was significantly more frequent among survivors than among non-survivors (93.7% vs. 87.4%; p = 0.020). Additionally, appropriate targeted meropenem therapy was administered in 13.96% of cases and was significantly more frequent among survivors than non-survivors (18.40% vs. 9.91%; p < 0.001). Multivariate analysis identified higher SOFA score and multiorgan dysfunction—particularly respiratory failure—as independent risk factors for 30-day all-cause mortality; respiratory tract infection and shorter length of hospital stay were also associated with mortality. Survivors had a significantly longer hospital stay than non-survivors (5.92 vs. 3.61 days; p = 0.007) and a higher microbiological cure rate (40.21% vs. 23.89%; p < 0.001). Conclusion Although appropriate antibiotic coverage was more frequently observed among patients with favorable outcomes, severity of illness and organ dysfunction remained the primary determinants of survival. Appropriate empirical and targeted therapy, alongside optimal critical care management, should be emphasized in the treatment of these severe infections in regional settings.
Related
- Early-life vancomycin and meropenem treatment exert distinct effects on microbiota-gut-brain axis signalling in zebrafish larvae
- Meropenem as a non-guideline antibiotic: the factor associated with mortality of mortality in Listeria monocytogenes meningitis
- Convergent S318T substitution in ADC enzymes contributes to reduced meropenem susceptibility in epidemic IC2 Acinetobacter baumannii
- Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters
- Efficacy of Standard Meropenem Dosing in Healthcare-Associated Meningitis: Is It Universal?
BibTeX
@article{sakulkonkij2026evaluation,
title = {{Evaluation of appropriateness of meropenem treatment and outcomes among internal medicine patients in Thailand}},
author = {Parichart Sakulkonkij and Jackrapong Bruminhent},
journal = {BMC Infectious Diseases},
year = {2026},
month = jul,
doi = {10.1186/s12879-026-14040-9},
url = {https://doi.org/10.1186/s12879-026-14040-9},
note = {CC BY},
}
RIS
TY - JOUR
TI - Evaluation of appropriateness of meropenem treatment and outcomes among internal medicine patients in Thailand
AU - Parichart Sakulkonkij
AU - Jackrapong Bruminhent
PY - 2026
DA - 2026/07/01
JO - BMC Infectious Diseases
DO - 10.1186/s12879-026-14040-9
UR - https://doi.org/10.1186/s12879-026-14040-9
AB - Objective Carbapenems are commonly used empirically in referral hospitals; however, the appropriateness and outcomes of meropenem use in regional settings with rising multidrug resistance remain unclear. Methods A retrospective cohort study of 528 patients who received at least 1 dose of meropenem in the internal medicine ward at Lampang hospital, Thailand during the study period (1 August 2022 and 31 December 2022). Results A total of 528 patients were enrolled. Of these, 281 (53.22%) were survivors, while 247 (46.78%) were non-survivors. Gram-negative bacteria were the most common infections, with 28.2% susceptible to carbapenems. The most frequent pathogens were Acinetobacter baumannii (16.7%), followed by Escherichia coli (13.6%) and Klebsiella spp. (8.0%). Pneumonia (36.93%) and urinary tract infection (21.97%) were the most common sites of infection. Appropriate empirical meropenem use was significantly more frequent among survivors than among non-survivors (93.7% vs. 87.4%; p = 0.020). Additionally, appropriate targeted meropenem therapy was administered in 13.96% of cases and was significantly more frequent among survivors than non-survivors (18.40% vs. 9.91%; p < 0.001). Multivariate analysis identified higher SOFA score and multiorgan dysfunction—particularly respiratory failure—as independent risk factors for 30-day all-cause mortality; respiratory tract infection and shorter length of hospital stay were also associated with mortality. Survivors had a significantly longer hospital stay than non-survivors (5.92 vs. 3.61 days; p = 0.007) and a higher microbiological cure rate (40.21% vs. 23.89%; p < 0.001). Conclusion Although appropriate antibiotic coverage was more frequently observed among patients with favorable outcomes, severity of illness and organ dysfunction remained the primary determinants of survival. Appropriate empirical and targeted therapy, alongside optimal critical care management, should be emphasized in the treatment of these severe infections in regional settings.
SN - 1471-2334
ER -